eFFECTOR Therapeutics, Inc. (EFTR)
(Delayed Data from NSDQ)
$1.31 USD
-0.07 (-5.07%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $1.31 0.00 (0.00%) 6:06 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EFTR 1.31 -0.07(-5.07%)
Will EFTR be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for EFTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EFTR
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
EFTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
Other News for EFTR
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute
eFFECTOR Therapeutics GAAP EPS of -$2.16 beats by $0.01
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update